Founded in Indianapolis in 2014, Genezen is focused on supporting the demands of the current and future gene and cell therapy manufacturing market worldwide— making viral vector production accessible to both early-stage, growth-oriented companies and established industry leaders. Genezen offers the following capabilities, building on the company’s expansive knowledge and experience in the industry and working with the nation’s leading institutions:

  • Process Development
  • Analytical Development
  • cGMP Lentiviral and Retroviral Vector Manufacturing
  • Patient Sample Testing
  • Cell Therapy Manufacturing
  • Master Cell Bank Production and Expansion

We leverage our state-of-the-art facility to allow for flexible manufacturing capacity and scale-up supported for both adherent and suspension platforms using producer cell lines, cell factories, and fixed-bed bioreactors. With our goal to lead with science, Genezen’s core mission is to deliver life-changing therapies through flexible support for cell and gene therapies, from early-stage through to the clinic.